Lumos Pharma price target lowered to $10 from $14 at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Lumos Pharma to $10 from $14 and keeps an Overweight rating on the shares following the quarterly results. Cantor views results from LUM-210 as the key near-term value-creating event for Lumos and believes the data from will clearly guide the design of a relatively capital-efficient Phase 3 pivotal study that may be operationalized in 2H24, the analyst tells investors in a research note.